Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

ChiCTR2000030054-HCQ (Chen), 2020 ChiCTR2000030054

hydroxychloroquine (n=18) vs. standard of care (n=12)

randomized controlled trial   high risk of bias

Studied treatment

hydroxychloroquine
Hydroxychloroquine sulfate group 0.2 g BID × 10 days

Control treatment

standard of care
according to the Chinese Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (5th Edition)

Patients

COVID 19 all comers

Method

open-label

China, single center

Remark

Study planned to recruit 100 subjects with confirmed mild/moderate types ofCOVID-19. Study discontinuated after enrolling only 67 subjects with mild/moderate COVID-19Publication report only data on 48 patients with moderate type of COVID-19